PROSTOX Standard targets CFRT (37–45 fractions) and MHFRT (20–28 fractions), expanding a regimen-specific platform aimed at predicting late GU toxicity after EBRT in localized prostate cancer.

Your device does not support the audio. O’FALLON, Ill. — HSHS St. Elizabeth’s Hospital is proud to announce the 100th Aquablation therapy procedure, marking a significant milestone in the advancement ...

(UroToday.com) The 2024 ASTRO annual meeting included a session on optimizing the therapeutic ratio in prostate cancer, featuring a presentation by Dr. William Hall discussing dose-escalated pelvic ...

In a trial, the ProFocal device for intermediate-risk prostate tumor ablation had an 84% treatment success rate with low morbidity. Cooled laser focal therapy ablation using a novel device (ProFocal®; ...

Feb. 12, 2026 8:30 AM ETProfound Medical Corp. (PROF), PRN:CA “We are deeply grateful to INOVAIT for supporting a vision where AI‑enabled, image‑guided therapies like TULSA-PRO are not only developed ...

TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage innovator in interventional MRI (“iMRI”) procedures, is ...